Fuji Pharma (4554) · InitiativeFirst statedLatest Other Disclosures (2026-03-24): "Advanced"
Preparing for and Identifying the Next Growth Drivers
First written in FY2025-H1. 1 of 2 entries say "Advanced", first in 2026-03-24. Latest entry: 2026-03-24.
2entries
2years
1from disclosures
How it moved
Same theme, other companies
Exploring and developing the next growth driversA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-03-24AdvancedOther Disclosures
「Under this agreement, we will hold the rights to develop, manufacture and commercialize the covered product candidates in Japan, the ASEAN countries and South Korea, and will bear part of the research and development costs.」
The company has given concrete form to the development and assessment of multiple women’s healthcare candidates as potential next growth drivers, including rights to their development, manufacturing and commercialization, together with the related cost burden. - FY2025-H1First statedAnnual report
「Over the next 5 years, the company is pursuing four growth strategies: "expanding contributions to women's healthcare," "expanding contributions through the biosimilars business," "contributing earnings through the global CMO business," and "laying the groundwork for and identifying the next growth drivers."」
In addition to its existing women’s healthcare, biosimilar and global CMO businesses, the company stated for the first time that laying the groundwork for and identifying the next growth drivers would constitute a separate growth strategy for the next 5 years.